Send to a Friend

The Access to Insight Basic Research Grant with a value of € 70,000 is for basic science or translational research relevant to the understanding of the pathophysiology and treatment of haemostatic disorders. The grant can be used to cover salary and/or project costs over a 12–18 month period.

The research priorities are the interactions of blood coagulation components (cells and proteins) and treatment of haemophilia. Topics could include the following:

• In vitro and in vivo models to evaluate therapeutics for haemophilia and rare bleeding disorders
• Better understanding of novel agents for treating haemophilia
• Insights into the use of gene therapy for treating haemophilia
• Investigations into phenotypic variations in haemophilia clinical severity
• Molecular basis for inhibitor development in patients with haemophilia
• Mechanism of action of bypassing agents in the treatment of inhibitor patients
• The function and regulation of platelets in haemostatic disorders
• Platelet receptors and clotting factor interactions in haemostatic disorders
• Cell trafficking and bio-distribution of clotting factors

In order to maintain a focus on interactions of blood coagulation components and haemophilia treatment, Access to Insight basic research grants will not support research focused on:

• Products or technologies licensed or patented by competitors of Novo Nordisk
• Pathophysiology, diagnosis, and treatment of blood transmitted diseases
• Thrombotic disorders
• Diagnosis and treatment of von Willebrand disease and platelet disorders
  

Download or upload your application form here.

Please click here for more information about the application review process.

Grant

2011

2012

September 1st, 2010
Open for Applications

March 1st, 2011
Application Deadline

April-May 2011
Review and Selection

June 2011
Notification of Winner

September 2011
Funding Available